Prof. Kevin Harrington The Institute of Cancer Research, UK

Professor Kevin Harrington develops new treatments with a specific focus on head and neck cancer and melanoma. In the field of oncolytic virotherapy, he has led the clinical development of talimogene laherparepvec (T-VEC), reovirus (pelareorep), coxsackie A21 (Cavatak) and vaccinia virus. His laboratory interests include analysis of combination regimens of... read moreoncolytic virotherapy and conventional or experimental targeted therapies. He is principal investigator or co-investigator for many trials of anti-PD1/anti-PD-L1 and anti-CTLA4 immunotherapy alone or combination with radiotherapy/chemoradiotherapy or oncolytic virotherapy (T-VEC, Cavatak).
He is Joint Head of the Division for Radiotherapy and Imaging at The Institute of Cancer Research/Royal Marsden Hospital and NIHR Biomedical Research Centre theme lead for Targeted Physical Therapies. He is also an Honorary Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust.
Prof. Harrington studied medicine at St Bartholomew’s Hospital, London and conducted PhD studies on liposomal drug targeting at Hammersmith Hospital. He completed post-doctoral research at the Mayo Clinic, Minnesota before joining the ICR in 2001. Prof. Harrington is a Fellow of the Royal Colleges of Physicians and Radiologists and was appointed an NIHR Senior Investigator in 2016. He has published 385 peer-reviewed papers, 45 book chapters and has edited 3 books.